Trials / Completed
CompletedNCT05222204
DDP ip Combined With AG in PDAC With Peritoneal Metastasis
Intraperitoneal (IP) Cisplatin Combined With Intravenous Gemcitabine + Nab-paclitaxel in Patients With Pancreatic Cancer With Peritoneal Metastasis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 91 (actual)
- Sponsor
- Fudan University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
intraperitoneal (IP) Cisplatin combined with intravenous gemcitabine + nab-paclitaxel in patients with pancreatic cancer with peritoneal metastasis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | intraperitoneal (IP) Cisplatin combined with intravenous gemcitabine + nab-paclitaxel | intraperitoneal (IP) Cisplatin combined with intravenous gemcitabine + nab-paclitaxel in patients with pancreatic cancer with peritoneal metastasis |
Timeline
- Start date
- 2022-05-15
- Primary completion
- 2024-07-08
- Completion
- 2024-12-12
- First posted
- 2022-02-03
- Last updated
- 2025-05-22
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05222204. Inclusion in this directory is not an endorsement.